Sydney-based Pharmaxis (ASX:PXS) has announced the first patient has been dosed in its Phase 1 clinical trial of an anti‐fibrotic Lysyl Oxidase (LOX) inhibitor focused on treating pancreatic cancer. …
Latest Video
New Stories
-
MSD announces US$2.7bn acquisition of ArQule
December 11, 2019 - - Latest News -
Sanofi narrows focus and scraps R&D in heritage areas
December 11, 2019 - - Latest News -
Model the behaviour you demand of others
December 11, 2019 - - Latest News -
Invites to medicines policy review working group
December 10, 2019 - - Latest News -
AusBiotech: Cuts threaten business sustainability
December 10, 2019 - - Latest News -
New report says 'Pelosi plan' would reduce US life expectancy
December 10, 2019 - - Latest News -
Sanofi acquires Synthorx ahead of strategy update
December 10, 2019 - - Latest News